News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Neochord Raises $5 Million, Seeks $11 Million for Mitral Regurgitation Treatment


8/3/2011 9:01:52 AM

The market for cardiac surgery devices was valued at $2 billion in 2010. That includes surgery related to heart valve problems that require mitral valve repair to treat patients who suffer mitral regurgitation. One Minnesota company wants to take a portion of the mitral valve repair market by commercializing a minimally invasive cardiac surgery device for patients whose mitral valves have ruptured or become elongated. NeoChord recently raised $5 million and is seeking another $6 million, according to a recent regulatory filing. Based on an earlier interview with MedCity News, it appears the money will be used to gain European approval and pay for the U.S. application for an investigational device exemption and the subsequent pivotal trial.

Read at News Release

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES